Finotonlimab yemewe gukoreshwa mu kuvura kanseri y’umutwe n’ijosi ya squamous cell

Ku ya 8 Gashyantare 2025, Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi (NMPA) mu Bushinwa cyemeje umuti wa finotonlimab wa Sinocelltech Group Ltd, antibody ya programmed-death 1 (PD-1) monoclonal (mAb), kugira ngo ukoreshwe hamwe na chemotherapy ishingiye kuri platine nk'uburyo bwa mbere bwo kuvura kanseri y’umutwe n’ijosi isubira inyuma.

Finotonlimab ni antibody ya IgG4 yahinduwe umuntu ifite uburenganzira bwuzuye mu by’ubwenge. Nk’umuti mushya ufite uburenganzira ku giti cye, imiterere yawo ya molekile ni yihariye kandi ifite ibyiza byawo mu mikorere. Finotonlimab ifatana na PD-1 ifite imbaraga nyinshi, igafunga inzira ya PD-1/PD-L1, ikagarura kandi ikongera imikorere yo kwica ubudahangarwa bw’uturemangingo twa T, bityo ikabuza gukura kwa kanseri.

AIgerageza ryakozwe ku buryo butaziguye, ryakozwe ku buryo butunguranye, ryasuzumye imikorere n'umutekano wa finotonlimab (SCT-I10A), antibody ya monoclonal yateguwe mu buryo bwa programmed cell death 1 (PD-1), ivanze na cisplatin hamwe na 5-fluorouracil (C5F) mu kuvura R/M HNSCC ku murongo wa mbere. Abarwayi bujuje ibisabwa (n = 370) bashyizwe mu byiciro 2:1 ku buryo butunguranye kugira ngo bahabwe finotonlimab hamwe na C5F (n = 247) cyangwa placebo hamwe na C5F (n = 123). Impanuka y'ibanze yari ukubaho muri rusange (OS). Mu itsinda rya finotonlimab hamwe na C5F, OS yari amezi 14.1 (95% interval of confidence (CI) 11.1–16.4), ugereranije n'amezi 10.5 (95% CI 8.1–11.8) mu itsinda rya placebo hamwe na C5F. Igipimo cy’ibyago cyari 0.73 (95% CI 0.57–0.95, P = 0.0165), cyujuje ibipimo byagenwe mbere byo kuba indashyikirwa ku musaruro w’ibanze. Finotonlimab hamwe na C5F byagaragaje ko indashyikirwa ku buryo bugaragara ugereranije na C5F yonyine kandi byemewe ku musaruro wa R/M HNSCC, bishyigikira ikoreshwa ryayo nk'uburyo bwa mbere bwo kuvura R/M HNSCC. Ibi bisubizo byemeza imikorere n'umutekano w'uruvange rwa finotonlimab na C5F ku barwayi bo muri Aziya bafite R/M HNSCC.

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Email：myimmnet@163.com

Amareferensi

1.国家药品监督管理局 (nmpa.gov.cn)

2.Finotonlimab hamwe na chimiotherapie muri kanseri yo mu mutwe no mu ijosi isubira cyangwa yanduye: igerageza ry’icyiciro cya 3 | Ubuvuzi bw’ibidukikije